7 assets in T-Cell Large Granular Lymphocyte Leukemia

Therapeutic assets addressing T-Cell Large Granular Lymphocyte Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer T-Cell Large Granular Lymphocyte Leukemia	Dren Bio	P1/2	CCC (48)
Duvelisib T-Cell Large Granular Lymphocyte Leukemia	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Ruxolitinib T-Cell Large Granular Lymphocyte Leukemia	Memorial Sloan Kettering Cancer Center	P1	CC (43)
kt-333 T-Cell Large Granular Lymphocyte Leukemia	Kymera Therapeutics, Inc.	P1	NR ()